Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.3952W HIGH $37.83
Volume
231.15 K
Value Traded
7.24 M
Short % Float
51.42%
Days to Cover
4.8
+7.43%Week
+20.02%1 Month
+46.26%3 Month
+2.93%6 Month
-82.2%5 Year
-82.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
367.47 M
EPS (TTM)
-28.26
P/E Ratio
-
Ent. Value
265.43 M
Total Shares
11.61 M
Float Shares
6.09 M
Insiders
48.17%
Institutions
72.11%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SRZN Catalyst Timeline
Dated clinical, regulatory and corporate events for Surrozen, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Surrozen, Inc.
218Total events
10Upcoming
28Tier-1 (high impact)
2019 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Equity OfferingCorporate
Closing of second and final tranche of March 2025 private placement for ~$95.1 million gross proceeds
●IND SubmissionSZN-8141IND
Surrozen submits IND application to FDA for SZN-8141 in DME
diabetic macular edemasource ↗
▲IP Litigation RulingIP / Competition
PTAB denies institution of Merck's post-grant review petition
▲Milestone PaymentSZN-413Corporate
Boehringer Ingelheim achieved development milestone under SZN-413 license agreement
retinal diseasessource ↗
◆Oral PresentationPresentation
Surrozen management to present at H.C. Wainwright 4th Annual BioConnect Investor Conference
▲Milestone PaymentSZN-413Corporate
Received $5 million milestone payment from Boehringer Ingelheim for SZN-413 research milestone
retinal diseasessource ↗
◆Oral PresentationPresentation
Surrozen management to present at TD Cowen 46th Annual Healthcare Conference
◆Oral PresentationPresentation
Surrozen management to present at Guggenheim Emerging Outlook: Biotech Summit 2026
◆Oral PresentationPresentation
37th Annual Piper Sandler Healthcare Conference Fireside Discussion
◆Oral PresentationPresentation
Surrozen management to present at Guggenheim 2nd Annual Healthcare Innovation Conference
◆Oral PresentationPresentation
Surrozen management presentation at H.C. Wainwright 27th Annual Global Investment Conference
◆Oral PresentationPresentation
Surrozen management to present at Cantor Global Healthcare Conference 2025
◆Oral PresentationPresentation
Surrozen management to present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
▲Management ChangeCorporate
Appointment of Daniel Chao as VP and Head of Clinical Development
▲Patent GrantedIP / Competition
U.S. Patent No. 12,297,278 granted for tetravalent multi-specific Wnt surrogates
▼Program DiscontinuationSZN-043DiscontinuedCorporate
Discontinuation of SZN-043 development in severe alcohol associated hepatitis
severe alcohol associated hepatitissource ↗
◆Topline ReadoutSZN-043DiscontinuedClinical Data
Phase 1b data in expanded study expected in 1H 2025
severe alcohol-associated hepatitissource ↗
▼Program DiscontinuationSZN-043DiscontinuedCorporate
Discontinued development of SZN-043 due to insufficient clinical benefit in Phase 1b trial
severe alcohol-associated hepatitissource ↗
●Poster PresentationSZN-8141Presentation
Preclinical data for SZN-8141 presented at ARVO 2025
retinal diseasessource ↗
●Oral PresentationPresentation
Preclinical data for SZN-8141 and SZN-8143 presented at Clinical Trials Summit
retinal diseasessource ↗
◆Development Candidate NominationSZN-413Preclinical
Potential nomination of lead Fzd-4 targeted Wnt agonist development candidate
Retinal diseasessource ↗
▲Milestone PaymentSZN-413Corporate
Potential $10M milestone payment from Boehringer Ingelheim upon development candidate nomination
Retinal diseasessource ↗
▲Enrollment UpdateSZN-043DiscontinuedTrial
Substantial enrollment progress in Phase 1b trial of SZN-043
severe alcohol-associated hepatitissource ↗
▲Enrollment CompleteSZN-043DiscontinuedTrial
Cohort 1 completed enrollment in Phase 1b trial of SZN-043
severe alcohol-associated hepatitissource ↗
▲Safety Data UpdateSZN-043DiscontinuedClinical Data
No drug-related SAEs in cohort 1 of Phase 1b trial
severe alcohol-associated hepatitissource ↗
▲Partnership / LicenseCorporate
Research collaboration with TCGFB to discover antibody therapeutics targeting TGF-β
idiopathic pulmonary fibrosissource ↗
▲Milestone PaymentSZN-413Corporate
Received $10 million milestone payment from Boehringer Ingelheim for SZN-413
retinal vascular associated diseasessource ↗
▲Milestone PaymentSZN-413Corporate
Boehringer Ingelheim advances SZN-413 development, triggering $10M milestone payment
retinal vascular diseasessource ↗
●PublicationPresentation
Publication of review article in iScience on Wnt activating platforms
◆Enrollment UpdateSZN-043DiscontinuedTrial
Enrollment ongoing in Phase 1b study
severe alcohol-associated hepatitissource ↗
Past FDA Catalysts and PDUFA Decisions
How SRZN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-02 | SZN-8141 (Fzd4/VEGF) | IND Clearance | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 78%
Micro Cap(rank 526 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SZN-8141 BiologicsNCT07817121 | Diabetic Macular Edema (DME) | Phase 1 | NOT YET_RECRUITING | 9 | Aug 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every SRZN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SZN-043 | liver cirrhosis | Phase 1a | 2024-06-10 | 40 healthy volunteers; 8 patients with a history of liver cirrhosis; doses ranged from 0.5 mg/kg to 3 mg/kg; mild-to-moderate, transient, and dose-related serum transaminase elevations; increased methacetin clearance; increases in alkaline phosphatase (ALP); increases in the portal hepatic filtration rate (HFR)Read More | Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in MilanRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TCG Crossover GP II, LLC10% Owner | Sell | -162,500 574,047 held | $21.25 | 07/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SRZN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 0.9 % (-25 %) | 38.23 M | 1.47 M |
Ownership Trends
SRZN Short Interest
Shares sold short, counted twice a month.
51.42%
Short % of Float
of tradable shares sold short
3.1M
Shares Sold Short
+43.0% vs prior count
4.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
656.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SRZN ranks across every disease it competes in
Competitive Position is a premium feature
See how SRZN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSRZN News
SRZNSurrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
Surrozen, Inc. closed the second tranche of its March 2025 private placement, raising approximately $95.1 million. This funding follows FDA clearance of the IND application for SZN-8141, enabling the company to advance its ophthalmology pipeline. Surrozen expects to maintain a cash runway into 2029, supporting ongoing clinical studies.
Read more →SRZNSurrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen, Inc. announced that its Investigational New Drug (IND) application for SZN-8141 has been cleared by the FDA, allowing the company to proceed with clinical development. The first patient is expected to be dosed in the DUET Phase 1b/2a study for diabetic macular edema in Q4 2026. This milestone also triggers a private placement closing expected to raise approximately $95.1 million.
Read more →SRZN▼ -9.1%on this news
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen, Inc. has submitted an IND application to the FDA for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist, aimed at treating diabetic macular edema. The drug is designed to address vascular leakage and promote retinal integrity through its dual mechanisms. A Phase 1b/2a clinical trial, named DUET, is set to begin by the end of 2026, with initial data expected in 2027.
Read more →SRZNSurrozen to Present at Upcoming Healthcare Investor Conferences
Surrozen, Inc. announced its participation in two upcoming healthcare investor conferences, including the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference. The presentations will provide insights into the company's pioneering work in targeted therapeutics for sight-threatening ophthalmic conditions. Surrozen aims to leverage Wnt signaling to address unmet medical needs in ocular diseases.
Read more →SRZN▲ +18.4%on this news
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
Surrozen, Inc. reported its financial results for Q2 2026, highlighting plans for an IND submission for SZN-8141 by Q3 2026 and the initiation of the DUET Phase 1b/2a study in diabetic macular edema by year-end 2026. The company also received a favorable ruling from the U.S. Patent Trial and Appeal Board regarding its patent. Despite an increase in operating expenses, Surrozen's cash position remains strong.
Read more →SRZNSurrozen to Present at Upcoming Healthcare Investor Conference
Surrozen, Inc. announced its participation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026. The presentation will focus on their innovative Wnt-based therapeutics aimed at treating sight-threatening conditions. Interested parties can access the audio webcast via Surrozen's website, with a replay available for 30 days.
Read more →SRZNSurrozen to Present at Upcoming Healthcare Investor Conference - May 12, 2026
Surrozen, Inc. will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company focuses on developing targeted therapeutics that harness Wnt signaling to treat sight-threatening ophthalmic conditions. Interested parties can access the live audio webcast through Surrozen's website.
Read more →SRZN▼ -9.9%on this news
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update
Surrozen, Inc. reported its Q1 2026 financial results, highlighting a cash position of $106.9 million and plans to submit an IND application for SZN-8141 for retinal diseases later this year. Despite a significant net loss of $127.5 million, the company remains focused on advancing its pipeline of ophthalmology therapeutics targeting unmet medical needs. The partnership with Boehringer Ingelheim for SZN-413 further strengthens its development efforts.
Read more →SRZNSurrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 28, 2026
Surrozen, Inc. announced the grant of a non-statutory stock option for 2,020 shares to a new non-executive employee as part of its 2025 Equity Inducement Plan. This grant, approved by the Board's Compensation Committee, aims to attract talent and is priced at $28.14 per share. The stock option vests over four years, reflecting the company's commitment to its workforce and future growth.
Read more →SRZNSurrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Surrozen, Inc. reported its financial results for Q4 and full year 2025, highlighting significant progress in its ophthalmology pipeline. The company plans to submit an IND application for SZN-8141 in the second half of 2026 and has received a milestone payment from Boehringer Ingelheim for SZN-413. Despite a substantial net loss, Surrozen's cash reserves have increased, indicating a strong financial position for future developments.
Read more →SRZNSurrozen to Present at Upcoming March 2026 Healthcare Investor Conference
Surrozen, Inc. announced its participation in the TD Cowen 46th Annual Healthcare Conference on March 4, 2026. The company will present a fireside chat at 1:10 PM Eastern Time. Surrozen focuses on developing Wnt-based therapeutics for sight-threatening ophthalmic conditions, showcasing its commitment to addressing unmet medical needs.
Read more →SRZNSurrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 23, 2026
Surrozen, Inc. announced the grant of a non-statutory stock option for 3,070 shares to a new non-executive employee as an inducement for employment. This grant, approved by the Compensation Committee, is part of Surrozen's 2025 Equity Inducement Plan and allows the purchase of shares at $24.53 each. The stock options vest over four years, promoting employee retention.
Read more →SRZN▲ +7.3%on this news
Surrozen to Present at Upcoming February 2026 Healthcare Investor Conference
Surrozen, Inc. announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, scheduled for February 12, 2026. The presentation will focus on the company's innovative Wnt-based therapeutics aimed at treating sight-threatening ophthalmic conditions. Interested investors can access the live audio webcast through Surrozen's website.
Read more →SRZN▼ -6.3%on this news
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Surrozen, Inc. announced the grant of stock option awards to its new CFO, Andrew P. Maleki, as part of its 2025 Equity Inducement Plan. The grant covers 50,000 shares at a price of $12.94 each and vests over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting top talent.
Read more →SRZNSurrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
Surrozen, Inc. reported its third quarter 2025 financial results, highlighting a net loss of $71.6 million. The company is focused on advancing its ophthalmology pipeline, particularly with its product candidates SZN-8141, SZN-8143, and SZN-413. Surrozen has strengthened its leadership team and secured a partnership with Boehringer Ingelheim to enhance its development capabilities.
Read more →SRZNSurrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Surrozen, Inc. announced the granting of inducement stock option awards covering 45,710 shares of common stock to four newly hired employees under its 2025 Equity Inducement Plan. These awards, sanctioned by the company's Compensation Committee, are intended to incentivize talent acquisition in line with Nasdaq Listing Rule 5635(c)(4). Each stock option grants access to shares at a set price of $12.32. Surrozen focuses on pioneering tissue-specific therapies for severe eye diseases, enhancing its growth prospects in the biotechnology sector.
Read more →About Surrozen, Inc.
Headquarters171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next SRZN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime